Plus Therapeutics, Inc.
NASDAQPSTV short interest utilization hits 100%, the highest level in 52 weeks, as availability plummets to 2.1% — signaling extreme difficulty borrowing shares.
Plus Therapeutics enters the back half of May with its lending pool fully locked, borrowing costs at extreme levels, and a fresh earnings miss dragging the stock to a 14% weekly loss. The clearest pressure point is the…
Every share of PSTV (Plus Therapeutics) available to borrow has been lent out. The lending pool is now completely exhausted — availability has dropped to 0%. Cost to borrow stands at 180% annualised, more than double…
Snapshot as of 30 Jun 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PSTV — free to start on ORTEX.
Sign up for free →Open PSTV on ORTEX